A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
Launched by NOVO NORDISK A/S · Sep 28, 2020
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- • The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
- • Male patients of all ages, according to local label, are allowed in this study
- • Diagnosis of severe or moderate Haemophilia A
- Exclusion Criteria:
- • Previous participation in this study. Participation is defined as having given informed consent in this study
- • Known or suspected hypersensitivity to N8-GP or related products
- • Mental incapacity, unwillingness or language barriers precluding adequate understanding and cooperation
- • Clinical suspicion or presence of FVIII inhibitors at time of inclusion
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vicenza, , Italy
Torino, , Italy
Ljubljana, , Slovenia
Zagreb, , Croatia
Porto, , Portugal
Lisboa, , Portugal
Zürich, , Switzerland
Wien, , Austria
Athens, , Greece
Málaga, , Spain
Budapest, , Hungary
Bonn, , Germany
Vicenza, , Italy
Tallinn, , Estonia
Berlin, , Germany
Vilnius, , Lithuania
Brno, , Czechia
Sofia, , Bulgaria
Kosice, , Slovakia
Vilnius, , Lithuania
Tallinn, , Estonia
Málaga, , Spain
Bonn, , Germany
Athens, , Greece
Hradec Kralove, , Czechia
Vilnius, , Lithuania
Tartu, , Estonia
Kaunas, , Lithuania
Parma, , Italy
Panevezys, , Lithuania
Athens, , Greece
Wien, , Austria
Berlin, , Germany
Kaunas, , Lithuania
Porto, , Portugal
Málaga, , Spain
Athens, , Greece
Parma, , Italy
Sofia, , Bulgaria
Zagreb, , Croatia
Brno, , Czechia
Budapest, , Hungary
Torino, , Italy
Hradec Kralove, , Czechia
Tartu, , Estonia
Panevezys, , Lithuania
Lisboa, , Portugal
Kosice, , Slovakia
Ljubljana, , Slovenia
Zürich, , Switzerland
Bonn, , Germany
Berlin, , Germany
Kosice, , Slovakia
Porto, , Portugal
Patients applied
Trial Officials
Clinical Transparency (1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials